An exploratory analysis from a phase III trial CLEOPATRA suggests that pertuzumab, trastuzumab, and docetaxel in a one line setting in HER2-positive advanced breast cancer delays the onset of CNS [50]. The gene discussed is ERBB2; the disease is breast carcinoma.